Ignite Creation Date:
2025-12-24 @ 9:09 PM
Ignite Modification Date:
2026-01-25 @ 10:48 PM
Study NCT ID:
NCT02605304
Status:
TERMINATED
Last Update Posted:
2018-05-02
First Post:
2015-11-12
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
Sponsor:
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-02-17
Start Date Type:
ACTUAL
Primary Completion Date:
2017-01-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-03-20
Completion Date Type:
ACTUAL
First Submit Date:
2015-11-12
First Submit QC Date:
None
Study First Post Date:
2015-11-16
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-01-10
Results First Submit QC Date:
None
Results First Post Date:
2018-02-15
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-04-02
Last Update Post Date:
2018-05-02
Last Update Post Date Type:
ACTUAL